Allogene Therapeutics, Inc.

Symbol: ALLO

NASDAQ

2.86

USD

Market price today

  • -1.4886

    P/E Ratio

  • 0.0000

    PEG Ratio

  • 488.27M

    MRK Cap

  • 0.00%

    DIV Yield

Allogene Therapeutics, Inc. (ALLO) Stock Split, History Data

Working capital analysis

In terms of working capital, Allogene Therapeutics, Inc. maintains a healthy position. The total current assets of the company are valued at $459115000. This represents a growth rate of -13.182% compared to the previous year. Breaking down the current assets, the cash and investments are worth $83155000, exhibiting a growth rate of -85.575% year-on-year. The year-on-year growth rate for receivables is -100.000%. This represents a healthy year-on-year growth of -100.000% On the liabilities side, the company's current liabilities total $37079000. This reflects a growth rate of -31.988% over the previous year, indicating the company's financial obligations are well under control.

202320222021202020192018
Cash and investments
83.16
576.47
809.48
1032.12
588.86
721.35
Receavebles
0.00
3.30
6.00
2.80
2.40
3.11
Inventory
0.00
62.45
20.02
207.01
60.73
261.97
Other
10.42
11.50
14.02
17.22
14.04
5.49
Total Current Assets
459.12
528.82
809.48
845.13
544.58
467.98
Acc Payable
5.90
13.89
10.26
10.39
9.25
12.34
Short Term Debt
6.78
6.00
3.20
2.97
0.00
0.00
Other Current Liab
24.32
33.74
34.30
41.96
23.83
17.12
Current Liabilities
37.08
54.52
48.17
94.32
33.08
29.46

Capital Structure

When examining the capital structure of Allogene Therapeutics, Inc., it is clear that the company manages a robust portfolio. These earnings represent the profits that Allogene Therapeutics, Inc. has chosen to reinvest in the business rather than distribute as dividends.

Total Assets

$NaN

Total liabilities

$NaN

Long term debt

$NaN

Cash and eqv

$NaN

Goodwill

$NaN

Retained earnings

$NaN

Common stock

$NaN

Enterprise Value

-$1.57

Frequently Asked Question

What is the latest historical split date of the company?

The latest historical split date is N/A.

What is firm free cah flow per share (FCF per share)?

The free cah flow per share (FCF per share) is -1.421.

What is company revenue per share?

The company revenue per share is -1965.169.

What are firm earnings per share?

The firm earnings per share is 0.999.

What is Allogene Therapeutics, Inc. (ALLO) ROIC (return on capital)?

Allogene Therapeutics, Inc. (ALLO) ROIC (return on capital) is -0.519.

What is dividend per share figure?

The dividend per share is 0.000

What is enterprise plowback ratio?

Allogene Therapeutics, Inc. (ALLO) plowback ratio is N/A

What is firm enterprise value (EV)?

The enterprise value (EV) is -1.568

What is company debt to equity ratio?

The debt to equity ratio is 0.186

What are debt ratio numbers?

The debt ratio is 0.148

What is company price to sales ratio?

The price to sales ratio is 3051.674